BEUDAMED
    FDA Adverse Event Injury Summary report: N

    HEMOLUNG RAS

    MDR report key: 16200041 · Received January 18, 2023

    Report

    Report Number
    3009763347-2023-00064
    Event Type
    Injury
    Date Received
    January 18, 2023
    Date of Event
    May 29, 2020
    Report Date
    January 18, 2023
    Manufacturer
    ALUNG TECHNOLOGIES, INC.
    Product Code
    QLN
    UDI-DI
    00850046004346
    PMA / PMN Number
    DEN210006
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    NJ, US
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    ALUNG TECHNOLOGIES, INC. MANUFACTURES THE HEMOLUNG RAS AND CATHETER. THE INCIDENT OCCURRED IN NEW BRUNSWICK, NEW JERSEY . MEDICAL INTERVENTION WAS REQUIRED TO PREVENT FURTHER PATIENT INJURY. THROUGH REVIEW OF THE EXPANDED ACCESS FORM ALUNG TECHNOLOGIES, INC. RECEIVED A REPORT THAT A PATIENT EXPERIENCED ANEMIA DURING EUA HEMOLUNG THERAPY. THIS EVENT REQUIRED TWO UNITS OF BLOOD BUT DID NOT RESULT IN HEMOLUNG THERAPY DISCONTINUATION. THE DATA LOG FROM HEMOLUNG THERAPY HAS BEEN RETRIEVED AND REVIEWED BY BOTH CLINICAL AND SOFTWARE ENGINEERING STAFF. NO ABNORMALITIES WERE NOTED WITHIN THE CO2 REMOVAL AND BLOOD FLOW GRAPHS. NO CRITICAL ERRORS OCCURRED. HEMOLUNG THERAPY WAS PROVIDED AS INTENDED. NO CAPA WAS OPENED BECAUSE OF THIS EVENT. ANEMIA IS A KNOWN POSSIBLE COMPLICATION ASSOCIATED WITH USE OF EXTRACORPOREAL HEMOLUNG THERAPY. EXAMINATION OF THE CONTROLLER DATA LOG SHOWS THAT HEMOLUNG THERAPY WAS PROVIDED AS INTENDED. ALUNG TECHNOLOGIES, INC. WILL CONTINUE TO MONITOR ANY ISSUES AS THEY ARE REPORTED. THIS MDR IS BEING FILED IN RESPONSE TO A RETROSPECTIVE VIEW OF ALL ALUNG TECHNOLOGIES, INC. COMPLAINTS, WHICH IDENTIFIED THAT THE REPORTING DECISION FOR THIS COMPLAINT WAS NOT CORRECT. THIS MDR IS BEING FILED RETROSPECTIVELY TO CORRECT THE ERROR IN THE REPORTING DECISION

    Description of Event or Problem · 0

    ALUNG TECHNOLOGIES, INC. RECEIVED A REPORT THAT A PATIENT EXPERIENCED ANEMIA DURING EUA HEMOLUNG THERAPY. THIS EVENT REQUIRED TWO UNITS OF BLOOD BUT DID NOT RESULT IN HEMOLUNG THERAPY DISCONTINUATION.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    362762 HEMOLUNG RAS EXTRACORPOREAL SYSTEM FOR CARBON DIOXIDE REMOVAL FOR THE TREATMENT OF COVID-19 QLN ALUNG TECHNOLOGIES, INC. HL-CR4-01-000 PART NUMBER 00850046004346

    Patients

    Seq Age Sex Outcome Treatment
    1 52 YR Female Required Intervention| L